Generic Name and Formulations:
Lipid content 0.2g/mL (refined soybean oil); emulsion for IV infusion; contains aluminum.
Indications for INTRALIPID:
To provide a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (≥5 days). To provide a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD).
Administer by IV infusion via a peripheral or central vein. Initiate rate at 0.5mL/min for the first 15–30mins; if tolerated, may increase to 1mL/min. Do not infuse >500mL on first day; if tolerated, may increase dose the next day; max: 2.5g/kg/day. EFAD: supply 8–10% of caloric input with Intralipid 20%. For complete parenteral nutrition: supplement with amino acids, carbohydrates, electrolytes, multivitamins and trace elements.
Administer by IV infusion via a peripheral or central vein. Premature infants: initially 0.5g/kg/day; may increase based on ability to eliminate fat; max: 3g/kg/day. Older children: initiate rate at max 0.05mL/min for the first 10–15mins; if tolerated, may increase to 0.5mL/kg/hr. Max dose: 3g/kg/day. EFAD: supply 8–10% of caloric input with Intralipid 20%. For complete parenteral nutrition: supplement with amino acids, carbohydrates, electrolytes, multivitamins and trace elements.
Disturbances of normal fat metabolism (eg, pathologic hyperlipemia, lipoid nephrosis, acute pancreatitis if accompanied by hyperlipidemia).
Risk of deaths in preterm and low birth weight infants: see full labeling. Severe liver damage, pulmonary disease, anemia, blood coagulation disorders, or when there is danger of fat embolism. Monitor serum triglycerides, liver function in long-term use (discontinue if impaired), platelet counts in neonates. Pregnancy (Cat.C). Nursing mothers.
Sepsis, vein irritation, dyspnea, cyanosis, allergic reactions, hyperlipemia, hypercoagulability, nausea, vomiting, headache, flushing, increase in temperature, sweating, sleepiness, chest and back pain, dizziness, liver dysfunction, blood dyscrasias; aluminum toxicity (esp. preterm infants, renal impairment).
Emulsion (100mL, 250mL, 500mL)—1
Neurology Advisor Articles
- Optimizing Treatment for Patients With Chronic Sciatica: Gabapentin vs Pregabalin
- Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis
- Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions
- A New Look at Demyelination and White Matter Density in Multiple Sclerosis
- Early Onset of Efficacy After Erenumab Treatment in Chronic and Episodic Migraines